VILNIUS, Lithuania–( BUSINESS WIRE )–Pulsetto, a rapidly growing consumer neurotechnology company, today shared a company update highlighting significant commercial growth and a sharpened strategic vision as it enters the next phase of global expansion.
The company is raising revenue from around $9 million in 2024 to more than $40 million in 2025.
Share it
The company is growing revenue from around $9 million in 2024 to more than $40 million in 2025, representing more than 4x year-over-year growth, while surpassing 300,000 users worldwide. At the same time, Pulsetto doubled the size of its team with expansion in engineering and medical research. The company has also been recognized by Deloitte as a Company to Watch and included in the Deloitte Technology Fast program, underscoring its momentum in the global healthtech landscape.
Building Future Stress Resilience
Pulsetto helped define a new category often called “stress fitness,” which is the idea that the nervous system can be actively trained through consistent daily exercise, like physical fitness. Designed for seamless integration into daily routines, the device supports stress management, recovery, and sleep readiness, building physiological resilience through the vagus nerve without medication.
“We are entering a pivotal growth phase,” said Ignace Brazdauskas, CEO of Pulsetto. “What’s important now is not just scale, but scale with focus. We see a clear opportunity to define and lead the Stress Fitness category.
The Science of Driving Real Results
Central to Pulsetto’s growth strategy is continued investment in clinical research and scientific credibility. The company has completed several studies examining the effects of non-invasive vagus nerve stimulation, with findings showing:
-
56% reduction in perceived stress
-
45% reduction in anxiety
-
41% improvement in sleep quality over four weeks
Additional studies have shown meaningful improvements in heart rate variability, migraine frequency, and pain management, across everyday health and more complex health conditions.
Jūratė Kiršė, Head of Clinical Research & Regulatory Strategy, commented: “Our focus is on creating solutions that truly improve people’s daily lives. We are committed to working with researchers and clinicians to ensure Pulsetto remains innovative and scientifically credible. Long-term trust comes from transparency, rigorous research, and real-world results.”
Looking ahead
As demand for non-invasive, drug-free wellness solutions continues to grow, Pulsetto is investing in product innovation, clinical research, and global distribution to support the next phase of its expansion.
With the increasing overlap between health, wellness, and consumer technology, Pulsetto is positioning itself as a category leader in consumer neurotechnology – focused not only on tracking health, but actively improving it.
About Pulseto
Pulsetto is a health technology company focused on the practical application of neuromodulation. The device stimulates the vagus nerve – a key regulator of the parasympathetic nervous system – to help minimize the stress response and improve recovery. The company has experienced rapid growth, quadrupling income in 2025 compared to 2024. Pulsetto has also been recognized by Deloitte as a Company to Watch and as part of the Deloitte Fast Technology program, underscoring momentum and innovation in the global healthtech landscape.
#Pulsetto #Exceeds #40M #Revenue #Moves #Define #Stress #Fitness #Category